A detailed history of 1620 Investment Advisors, Inc. transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 1,000 shares of AVDL stock, worth $12,020. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,000
Previous 1,000 -0.0%
Holding current value
$12,020
Previous $14,000 7.14%
% of portfolio
0.01%
Previous 0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

BUY
$14.06 - $18.82 $14,060 - $18,820
1,000 New
1,000 $14,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $728M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track 1620 Investment Advisors, Inc. Portfolio

Follow 1620 Investment Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 1620 Investment Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on 1620 Investment Advisors, Inc. with notifications on news.